Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $55.06.

KYMR has been the subject of several analyst reports. Stephens reaffirmed an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Morgan Stanley increased their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. BTIG Research began coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Guggenheim increased their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company.

Kymera Therapeutics Stock Up 0.7 %

Shares of NASDAQ KYMR opened at $36.88 on Monday. Kymera Therapeutics has a 12 month low of $29.24 and a 12 month high of $53.27. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -15.76 and a beta of 2.18. The business has a fifty day simple moving average of $40.41 and a 200-day simple moving average of $44.22.

Insider Activity

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 15.82% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. grew its holdings in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $61,000. KBC Group NV grew its holdings in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the last quarter. Quarry LP acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.